FSBSI Russian Oncological Scientific Center n.a. N.N. Blokhin
Moscow 115478
0 studies enrolling now · 11 studies all time
What they study most
Advanced BRAFV600 Wild-type Melanoma, Biliary Tract Cancer, Breast Cancer, First Line Non-Small Cell Lung Cancer, Gastric Adenocarcinoma, Melanoma, Metastatic Breast Cancer, Prostate Cancer, Solid Tumor, Triple Negative Breast Cancer, Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
Studies at this site
- Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] — Running, not enrolling
- Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC — Running, not enrolling
- Avelumab in First-line NSCLC (JAVELIN Lung 100) — Completed
- Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma — Stopped early
- Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial) — Stopped early
- Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer — Stopped early
- A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma — Stopped early
- A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease — Stopped early
- Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) — Completed
- A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma — Completed
- Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer — Completed